Chronic urticaria is one of the few conditions that dermatologists, allergists and primary care clinicians all claim and all inherit. The patient often sees each of them before anyone owns the plan. That makes it a good test of how well specialties hand patients to each other.
What is chronic urticaria?
Chronic urticaria is wheals, angioedema or both, recurring for more than six weeks. The 2026 international guideline describes urticaria as a mast cell-driven disease and splits the chronic form into two groups (Zuberbier et al., Allergy, 2026).
- Chronic spontaneous urticaria (CSU): no identifiable external trigger. Wheals appear on their own.
- Chronic inducible urticaria (CIndU): a specific, reproducible trigger. Examples include symptomatic dermographism, cold, heat, pressure, sun and cholinergic urticaria.
The American College of Allergy, Asthma and Immunology estimates chronic hives affect about 1.4% of the general population, with women affected about twice as often as men. Most patients never get a single identified cause, and food is rarely the driver.
Where angioedema fits
Angioedema is deeper swelling of the lower dermis, subcutaneous tissue or mucosa. It tends to burn or feel tight more than it itches, and it resolves more slowly than a wheal. In chronic urticaria it is mast cell mediated.
Recurrent angioedema without wheals is a different question. The 2026 AAAAI/ACAAI Joint Task Force guideline lists bradykinin-mediated causes, such as ACE inhibitor-associated angioedema, hereditary angioedema and acquired C1-inhibitor deficiency, in the differential. These do not respond to antihistamines, and missing them carries real risk.
The wheal belongs to dermatology. The mast cell belongs to both.
What is the mast cell doing?
Releasing mediators into the skin, repeatedly, without a good reason. Skin mast cells hold histamine and other preformed mediators, and they produce prostaglandins, leukotrienes and cytokines when activated. The result is the itch, flare and swelling the patient describes.
In CSU, the trigger for activation is often autoimmune. The current model includes IgE directed against self antigens and IgG autoantibodies directed against IgE or its high-affinity receptor on the mast cell. These endotypes help explain why patients respond differently to the same therapy.
This is the biology that the Dermato-Allergy Exchange tentative agenda (subject to change) gives two full parts in MC²: Mast Cell Master Class, one on physiology and pathobiology and one on current and emerging therapies.
How do dermatology and allergy approach workup and treatment?
With restraint in testing and a stepwise plan for therapy. Both the international guideline and the 2026 Joint Task Force guideline steer clinicians away from broad allergy panels and extensive lab testing in typical chronic urticaria.
The international guideline suggests a limited baseline for CSU, a differential blood count and CRP or ESR, with total IgE and IgG anti-thyroid peroxidase considered in specialist settings. The Joint Task Force puts more weight on a focused history and exam, reserving testing for a history that points to a specific trigger or another diagnosis. For CIndU, provocation testing confirms the subtype.
Dermatology tends to start from the skin: lesion morphology, duration of individual wheals and whether this is urticaria at all. A wheal that lasts days or leaves bruising raises urticarial vasculitis. Allergy tends to start from the trigger story and the angioedema history. Both questions matter. Patient-reported tools such as the Urticaria Activity Score (UAS7) and the Urticaria Control Test give both specialties a shared language.
Treatment, step by step
The goal is complete control. At the level of a CME overview, the current guidelines agree on the frame:
- Second-generation H1 antihistamines first, with updosing within guideline limits when control is incomplete.
- Advanced therapy for antihistamine-refractory disease. Options include an anti-IgE biologic, a biologic targeting type 2 inflammation and an oral BTK inhibitor, depending on the guideline and on licensing.
- Calcineurin inhibitors and other immunomodulators for selected refractory patients, typically under specialist care.
Both guidelines discourage maintenance systemic corticosteroids. The Joint Task Force goes further and says systemic steroid use should prompt urgent evaluation by a chronic urticaria specialist.
Why does the handoff matter?
Because the patient pays for every gap. A CSU patient bouncing between urgent care steroid bursts and specialty waitlists can lose months.
A good handoff carries the essentials: wheal duration, angioedema history, current medicines (including ACE inhibitors), antihistamine response and a control score. With that, the next clinician starts at step two, not step zero. The Joint Task Force guideline names both allergists and dermatologists as its audience.
The wheal belongs to dermatology. The mast cell belongs to both. For the full program built around that idea, read inside the DermIQ Dermato-Allergy Exchange. For another disease where the front door is rarely dermatology, see hidradenitis suppurativa and the long road to diagnosis.
What's next
Chronic urticaria, angioedema and mast cell disorders sit at the center of the DermIQ Dermato-Allergy Exchange, March 13 to 14, 2027, in Tysons Corner, VA. Registration is $99 for every clinician.
Education for every clinician who touches skin. Written for clinicians, not as advice for patients. Questions or a case to share? Write to us.
